557 / 1631
Gadolin Study (Bendamustine and Obinutuzumab) an
option in relapsed disease
Progression Free Survival (IRC)
Sehn, L. et al. Lancet Onc. 2016
•
The addition of obinutuzumab also improved PFS in patients that were refractory to
both alkylators and rituximab (double refractory) (HR 0.56 (0.40–0.78))